Investors

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (GBT440), for the treatment of sickle cell disease.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$46.76
Change (%)0.00 (0.00%)
Volume75
Data as of 01/15/19 4:00 p.m. ET
Refresh quote
Featured Events
Corporate Presentation
Download Documentation Corporate Presentation (January 2019)
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
01/03/19GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on January 1, 2019, the compensation committee of the Company’s board of directors granted three new employees options to purchase an aggregate of 6,000 shares of the Company’s common stock with a per share exercise price of $41.05 and restricted stock units for an aggregate of 3,950 shares of the Company’s common stock. All of the above-descri... 
Printer Friendly Version
01/02/19GBT to Present at the 37th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019, at 11:30 a.m. Pacific Time. The presentation and Q&A session will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for replay for one month following the event. About GBT GB... 
Printer Friendly Version
12/21/18GBT Appoints Dawn Svoronos to Board of Directors
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Dawn Svoronos to the company’s board of directors. Ms. Svoronos has more than 30 years of experience in the biopharmaceutical industry in the United States, Canada, Europe and Asia, including a nearly 25-year tenure at Merck & Co. “Dawn is a global biopharmaceutical leader whose addition to the board will strengthen the existing breadth of... 
Printer Friendly Version
12/07/18Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced the pricing of its underwritten public offering of its common stock for gross proceeds of approximately $150.0 million, before deducting the underwriting discounts and commissions and other estimated off... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.